Replies to post #16977 on Marker Therapeutics Inc (MRKR)

[waterboy1608]

Tesaro's stock nearly doubles toward record open after successful cancer treatment trial
https://research.tdameritrade.com/grid/public/markets/news/story.asp?docKey=1-SN20160629006085&cid=1-SN20160629006085-MIP

[Rkmatters]

It treats a specific Ovarian population. If TPIV targets that same patient population with TPIV200, and the standard of care changes, then each arm will get that new drug; and then TPIV would need to show an improvement upon that, and changes would be made to the protocol to address. As of right now, they are going after the entire Ovarian population that is in remission.This company is not. But TapImmune will address if it changes their game plan at all. It is likely to be synergistic to TPIV's treatment, and the combination could end up extending survival to be cure like.

http://www.publicnow.com/view/83D2FE90506382232956E0CD480AA3A40AD440F2